Why is GAAP EPS growth (38%) so much higher than Adjusted EPS growth (16%)?

GAAP EPS of $9.59 includes a $160 million pre-tax credit tied to the Rite Aid bankruptcy, which management excludes from adjusted results. That one-time credit, along with other items such as LIFO adjustments and amortization add-backs, widens the gap. Investors should focus on Adjusted EPS for run-rate operating performance.

What is driving the raised full-year guidance?

Management attributes the raise to strong third-quarter results and operating momentum, particularly in oncology and multispecialty distribution, including acquisition contributions and biopharma services. The guidance includes $0.09 of year-to-date gains from McKesson Ventures' equity investments, which are not recurring operating earnings.

Is the company's balance sheet or cash position a concern?

Cash fell sharply to $2.96B from $5.69B at March 2025, and long-term debt rose to $5.43B, largely due to $3.4B of acquisitions and continued shareholder returns. The company still has a stockholders' deficit, though it narrowed. Free cash flow of $2.2B over nine months provides some coverage, but investors should watch leverage and capital allocation priorities.

Which business is weakening and why?

The Medical-Surgical Solutions segment is the weak spot. Revenue rose just 1%, but adjusted segment operating profit fell 10% to $265M, driven by lower volumes across physician office settings and a milder cold and flu season. The segment is also being prepared for separation as an independent company.

What does the Norway divestiture mean for McKesson?

The January 30, 2026 closing of the sale of Norwegian retail and distribution businesses completes McKesson's exit from European operations, which was a stated strategic commitment. This simplifies the portfolio toward North American pharmaceutical distribution, oncology, and prescription technology, though the filing does not quantify the proceeds or the earnings impact.

MCK 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 4, 2026. Cited figures are marked; the original filing is the authoritative source.

McKesson (MCK) reported fiscal Q3 2026 results (quarter ended December 31, 2025) that beat on the strength of its core distribution businesses.

Revenue rose 11% to $106.2 billion^a, GAAP diluted EPS climbed 38% to $9.59 (helped by a $160 million pre-tax Rite Aid bankruptcy credit that is excluded from adjusted results), and Adjusted EPS grew 16% to $9.34. Operating income rose 32% to $1.62 billion, and nine-month revenue grew 15% to $307.1 billion. Growth was led by the Oncology & Multispecialty segment, where revenue rose 37% and adjusted segment operating profit rose 57%, and by North American Pharmaceutical, where revenue rose 9%.

Medical-Surgical Solutions was the weak spot, with adjusted segment operating profit down 10%. Cash generation was solid, with quarterly free cash flow of $1.1 billion^b and nine-month free cash flow of $2.2 billion. Management returned $2.4 billion to shareholders over nine months through $2.1 billion of buybacks and $280 million of dividends.

Balance sheet leverage increased: cash fell to $3.0 billion^c from $5.7 billion at March 31, 2025, long-term debt rose to $5.4 billion, and total stockholders' deficit improved only modestly. Acquisitions consumed $3.4 billion of cash over the nine months, mainly in oncology. Management raised and narrowed FY2026 Adjusted EPS guidance to $38.80–$39.20 from $38.35–$38.85, implying 17–19% growth.

The guidance includes $0.09^d of year-to-date gains from McKesson Ventures. Key strategic updates include the January 30, 2026 close of the Norwegian divestiture, which completes the exit from Europe, and the ongoing preparation to separate the Medical-Surgical Solutions segment as an independent company.

02—Key points

Key Highlights

Revenue up 11% to $106.2B in Q3 FY26; nine-month revenue up 15% to $307.1B, driven by prescription volume growth and oncology acquisitions.
Adjusted EPS of $9.34 rose 16% year over year; GAAP diluted EPS of $9.59 rose 38%, aided by a $160M pre-tax Rite Aid bankruptcy credit excluded from adjusted results.
Oncology & Multispecialty was the standout segment: revenue up 37% to $13.0B and adjusted segment operating profit up 57% to $366M.
FY26 Adjusted EPS guidance raised and narrowed to $38.80–$39.20 (from $38.35–$38.85), representing 17–19% growth.
Quarterly free cash flow of $1.1B; nine-month free cash flow of $2.2B, with $2.4B returned to shareholders via $2.1B of buybacks and $280M of dividends.
Balance sheet shifted: cash declined to $3.0B from $5.7B at March 2025 and long-term debt rose to $5.4B, while $3.4B was spent on acquisitions over nine months.
Completed the sale of Norwegian retail and distribution businesses on January 30, 2026, finalizing the exit from European operations; Medical-Surgical Solutions separation is progressing, though its adjusted segment profit fell 10%.

03—Questions

Frequently Asked Questions

Why is GAAP EPS growth (38%) so much higher than Adjusted EPS growth (16%)?
GAAP EPS of $9.59 includes a $160 million pre-tax credit tied to the Rite Aid bankruptcy, which management excludes from adjusted results. That one-time credit, along with other items such as LIFO adjustments and amortization add-backs, widens the gap. Investors should focus on Adjusted EPS for run-rate operating performance.
What is driving the raised full-year guidance?
Management attributes the raise to strong third-quarter results and operating momentum, particularly in oncology and multispecialty distribution, including acquisition contributions and biopharma services. The guidance includes $0.09 of year-to-date gains from McKesson Ventures' equity investments, which are not recurring operating earnings.
Is the company's balance sheet or cash position a concern?
Cash fell sharply to $2.96B from $5.69B at March 2025, and long-term debt rose to $5.43B, largely due to $3.4B of acquisitions and continued shareholder returns. The company still has a stockholders' deficit, though it narrowed. Free cash flow of $2.2B over nine months provides some coverage, but investors should watch leverage and capital allocation priorities.
Which business is weakening and why?
The Medical-Surgical Solutions segment is the weak spot. Revenue rose just 1%, but adjusted segment operating profit fell 10% to $265M, driven by lower volumes across physician office settings and a milder cold and flu season. The segment is also being prepared for separation as an independent company.
What does the Norway divestiture mean for McKesson?
The January 30, 2026 closing of the sale of Norwegian retail and distribution businesses completes McKesson's exit from European operations, which was a stated strategic commitment. This simplifies the portfolio toward North American pharmaceutical distribution, oncology, and prescription technology, though the filing does not quantify the proceeds or the earnings impact.

04—Continue

← View all 8-K filings